Back to Search
Start Over
Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria.
- Source :
-
The British journal of dermatology [Br J Dermatol] 2018 Sep; Vol. 179 (3), pp. 702-708. Date of Electronic Publication: 2018 Jun 15. - Publication Year :
- 2018
-
Abstract
- Background: Chronic spontaneous urticaria (CSU) is a skin disease with itchy hives and/or angio-oedema that last for at least 6 weeks without an obvious external trigger.<br />Objectives: To determine the cost-effectiveness of omalizumab relative to standard of care (SoC; up to four times the daily dose of H <subscript>1</subscript> -antihistamines) in the Netherlands from a societal perspective.<br />Methods: The Markov model used consisted of five health states based on Urticaria Activity Score over 7 days. Model settings and characteristics of the Dutch patient population were based on an online survey among clinical experts and were validated during an expert committee meeting. Transition probabilities were derived from the GLACIAL trial. Healthcare consumption, quality of life (using EuroQol-5D) and productivity losses were derived from a burden-of-illness study (ASSURE-CSU) among 93 Dutch patients. Healthcare consumption and productivity losses were evaluated using the Dutch costing manual. The comparator treatment was SoC, consisting of (updosed) antihistamines. A 10-year time horizon was used.<br />Results: The incremental cost-effectiveness ratio (ICER) of omalizumab vs. SoC was €17 502 per quality-adjusted life-year (QALY) gained. Productivity costs played an important role in the value of the ICER; discarding productivity costs resulted in an ICER of €85 310 per QALY.<br />Conclusions: Omalizumab is cost-effective compared with SoC. The outcomes of this study were used to establish omalizumab as third-line therapy in the Dutch treatment guidelines for CSU.<br /> (© 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)
- Subjects :
- Adult
Anti-Allergic Agents economics
Chronic Disease drug therapy
Chronic Disease economics
Cost of Illness
Drug Therapy, Combination economics
Drug Therapy, Combination methods
Efficiency drug effects
Health Care Costs statistics & numerical data
Histamine H1 Antagonists economics
Humans
Injections, Subcutaneous
Markov Chains
Models, Economic
Netherlands
Omalizumab economics
Patient Acceptance of Health Care statistics & numerical data
Quality of Life
Quality-Adjusted Life Years
Severity of Illness Index
Standard of Care economics
Urticaria diagnosis
Urticaria economics
Anti-Allergic Agents administration & dosage
Cost-Benefit Analysis
Histamine H1 Antagonists administration & dosage
Omalizumab administration & dosage
Urticaria drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2133
- Volume :
- 179
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The British journal of dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 29476533
- Full Text :
- https://doi.org/10.1111/bjd.16476